![cover image](https://wikiwandv2-19431.kxcdn.com/_next/image?url=https://upload.wikimedia.org/wikipedia/commons/thumb/f/f8/Cabozantinib.svg/640px-Cabozantinib.svg.png&w=640&q=50)
Cabozantinib
Chemical compound / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Cabozantinib?
Summarize this article for a 10 year old
Cabozantinib, sold under the brand names Cometriq and Cabometyx among others, is an anti-cancer medication used to treat medullary thyroid cancer, renal cell carcinoma, and hepatocellular carcinoma.[9][10] It is a small molecule inhibitor of the tyrosine kinases c-Met and VEGFR2, and also inhibits AXL and RET.[8][7] It was discovered and developed by Exelixis Inc.
![]() | |
Clinical data | |
---|---|
Trade names | Cometriq, Cabometyx, others |
Other names | XL184, BMS907351, cabozantinib s-malate |
AHFS/Drugs.com | Monograph |
MedlinePlus | a613015 |
License data |
|
Pregnancy category |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Protein binding | ≥99.7% |
Metabolism | Liver (CYP3A4-mediated) |
Elimination half-life | 110 hours |
Excretion | Feces (54%), urine (27%) |
Identifiers | |
| |
CAS Number |
|
PubChem CID | |
DrugBank |
|
ChemSpider | |
UNII |
|
KEGG | |
ChEBI |
|
ChEMBL |
|
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.221.147 ![]() |
Chemical and physical data | |
Formula | C28H24FN3O5 |
Molar mass | 501.514 g·mol−1 |
3D model (JSmol) | |
| |
|
In November 2012, cabozantinib in its capsule formulation was approved by the US Food and Drug Administration (FDA) under the name Cometriq for treating people with medullary thyroid cancer.[13][14] The capsule form was approved in the European Union for the same purpose in 2014.[11] In April 2016, the FDA granted approval for marketing the tablet formulation (Cabometyx) as a second line treatment for kidney cancer[15][16] and the same was approved in the European Union in September of that year.[12] The brands Cometriq and Cabometyx have different formulations and are not interchangeable.[17]